Continuing Education Activity

Genitourinary syndrome of menopause (GSM) is a term that encompasses a wide range of symptoms and conditions associated with changes in the genital and urinary systems due to the decline in estrogen levels during menopause. As women approach menopause, hormonal shifts—particularly the reduction in estrogen—can lead to structural and functional changes in the tissues of the vagina, vulva, bladder, and urethra. Previously called vulvovaginal atrophy, GSM more accurately captures the broader spectrum of symptoms that affect both the genital and urinary systems. These symptoms can include vaginal dryness, irritation, burning, painful intercourse (dyspareunia), recurrent urinary tract infections, and urinary incontinence. Many women hesitate to discuss these issues with healthcare professionals, despite their significant impact on quality of life. GSM is highly prevalent, affecting over half of women who are postmenopausal, yet it remains underdiagnosed and undertreated. The condition is progressive, and the symptoms often worsen over time without treatment. Various treatment options—ranging from nonhormonal lubricants and moisturizers to hormone replacement therapy—are available to alleviate symptoms and improve quality of life.

This activity reviews the identification, diagnosis, and management of GSM through a discussion of the physiological changes associated with menopause that lead to GSM, as well as the vast array of symptoms that can affect both the genital and urinary systems. The activity also highlights the role of the interprofessional team in improving the diagnosis and management of GSM, allowing for better patient outcomes and enhanced quality of care for menopausal women.

Objectives:

• Identify the etiology and epidemiology of genitourinary syndrome of menopause.
• Screen for genitourinary syndrome of menopause in postmenopausal women through comprehensive patient histories and physical examinations.
• Implement evidence-based treatment strategies for genitourinary syndrome of menopause, including both hormonal and nonhormonal therapies.
• Collaborate with an interprofessional team to support early intervention of genitourinary syndrome of menopause, achieving better long-term outcomes and empowering women to maintain a high quality of life throughout menopause and beyond.

Introduction

In 2014, the term "genitourinary syndrome of menopause" was recommended to describe sexual, genital, and urinary changes associated with the hypoestrogenism that occurs after menopause. This term has replaced older terminology, such as vulvovaginal atrophy and atrophic vaginitis.[1] Genitourinary syndrome of menopause (GSM) encompasses vulvovaginal atrophy, urogenital atrophy, and atrophic vaginitis, affecting the vagina, labia, urethra, and bladder due to low estrogen levels. GSM impacts 27% to 84% of postmenopausal women.[2] This condition is primarily caused by decreased estrogen levels in postmenopausal individuals or those of any age who experience reduced estrogenic stimulation of the urogenital tissues. The signs and symptoms of GSM can resemble those of other genitourinary conditions, potentially delaying the diagnosis and treatment.[3] GSM also alters the anatomy and physiology of the genitourinary system, necessitating a treatment approach that may include both nonhormonal and hormonal therapies.

Etiology

Estrogen plays a crucial role in maintaining the normal anatomy and physiology of the urogenital system. Estrogen receptors are present in the vagina, vulva, urethra, and bladder trigone, where they respond to estrogen stimulation by maintaining normal blood flow, tissue thickness, rugosity, elasticity, and moisture of epithelial surfaces. During the reproductive years, the vagina is rich in glycogen, which is converted by the normal flora, lactobacilli, into lactic acid. This process creates an acidic environment in the vagina, with a pH ranging from 3.5 to 5.0, allowing lactobacilli to continue to thrive and protect the vaginal and urinary tracts from infections. After menopause, the quantity of lactobacilli decreases, leading to an increase in the vaginal pH and the development of GSM.[2] 

Additionally, sexual activity promotes epithelial turnover and enhances vaginal lubrication. A decline in estrogen levels during menopause causes urogenital atrophy. As estrogen production decreases, secretions diminish, and the genitourinary tissues become atrophic, leading to the symptoms associated with GSM. Other causes of GSM include lactation, hypothalamic amenorrhea, and antiestrogen medications used in the treatment of uterine fibroids, endometriosis, and breast cancer.[3][4]

Epidemiology

GSM is a prevalent concern among the postmenopausal population. Study results indicate that while roughly 15% of women experience symptoms of vaginal atrophy before menopause, approximately 40% to 54% of postmenopausal individuals report bothersome symptoms. Menopause causes a dramatic 95% reduction in estrogen production, resulting in 75% of wo experiencing vaginal dryness, 40% reporting pain during intercourse, and 30% to 40% experiencing urinary urgency and frequency. Despite these symptoms, more than 50% of affected patients are not using any treatments to alleviate their discomfort.[5]

Approximately 70% of patients with signs and symptoms of GSM do not discuss their concerns with healthcare professionals.[6] Many patients feel reluctant or embarrassed to discuss or seek treatment, believing these symptoms are a normal part of aging. Cultural, religious, and societal beliefs also influence their willingness to discuss these quality-of-life issues. Additionally, many patients are unaware of available treatment options. As a result, less than 25% of affected women receive appropriate care. Clinicians often do not screen for symptoms of GSM. This omission leads to underdiagnosis and undertreatment of this condition.[2]

GSM most commonly arises from conditions that lead to a diminished estrogen state, such as natural menopause, where the ovaries cease estradiol production, resulting in a 95% decline in estradiol levels from premenopausal levels. However, GSM can also occur in individuals with other conditions associated with low estrogen, including those who have undergone surgical menopause following bilateral oophorectomy, primary ovarian insufficiency, chemotherapy, hypothalamic amenorrhea, or are breastfeeding. Additional risk factors include ovarian failure due to radiation or arterial embolization, hypothalamic-pituitary disorders, and the use of antiestrogen medications such as leuprolide or gonadotropin-releasing hormone antagonists, often prescribed for endometriosis. Breast cancer survivors, particularly, are at increased risk due to treatments such as chemotherapy or aromatase inhibitors, which can contribute to the early onset of GSM symptoms.[3][7][8]

Pathophysiology

Estrogen plays a critical role in maintaining healthy blood flow and a balanced microbiome in the vagina while maintaining the elasticity, thickness, and moisture of the vaginal epithelium by sustaining collagen levels. Estrogen also promotes the exfoliation of vaginal epithelial cells, leading to increased glycogen levels, which lactobacilli in the normal vaginal flora convert into lactic acid. This process allows for the renewal of the vaginal epithelium and maintains the vagina's typical acidic pH. When estrogen levels decline, this process is disrupted, resulting in an atrophic vaginal epithelium with reduced secretions and a less acidic environment characterized by a pH greater than 5.[8][9] These physiologic changes increase the risk of vaginal and urinary tract infections.

Traditionally, estrogen has been recognized as the primary hormone responsible for the health and function of the vagina. However, increasing evidence suggests that androgens also play a crucial role in maintaining urogenital tissue health. The vagina contains androgen receptors that, when stimulated, help reduce inflammation and maintain vaginal contractility. After menopause, dehydroepiandrosterone (DHEA), a weak androgen primarily secreted by the adrenal glands, becomes the prominent sex steroid in the body. Within the vagina, DHEA is converted into both estrogens and androgens. This understanding has led to a newer approach to GSM treatment, including local androgen therapy with DHEA.[10][11]

History and Physical

Diagnosing GSM requires a comprehensive patient history and a thorough physical examination. Laboratory testing is not required. Common symptoms include genital dryness, burning, and irritation. Patients may also experience pain and dryness during intercourse, as well as dysuria, urgency, and recurrent urinary tract infections. Many symptoms of GSM can be mistaken for other genitourinary conditions, such as vaginal or urinary tract infections, making it crucial for clinicians to obtain a detailed history, including a sexual history.[2] Inquiring about sexual habits and activities is important to rule out other causes, particularly infections. As GSM symptoms develop, many patients find sexual activity challenging due to changes in the vaginal mucosa, which can lead them to avoid vaginal intercourse, further exacerbating the atrophy.[8][9][12] 

Clinicians should ask about obstetric and gynecologic histories, menstrual history, current and past medications, and the use of any potential irritants in the area. Specific questions related to GSM symptoms should be addressed, as patients may not always volunteer this information without prompting. Symptoms of GSM may include dyspareunia, postcoital bleeding, and dysuria. A decrease in vaginal lubrication during sexual activities is often the first symptom, followed by discomfort during daily activities. Additionally, as the vaginal pH changes, the vaginal flora may also change, increasing the risk of recurrent urinary tract infections. Unlike vasomotor symptoms, which tend to improve over time, GSM is progressive without treatment.[2]

The anatomical changes associated with GSM can include fusion of the labia major or minora, introital stenosis, labial and clitoral atrophy, phimosis of the prepuce, and urethral caruncles, polyps, eversion, or prolapse. The urethral meatus may become susceptible to physical irritation.[1] Vaginal changes may include tissue fragility and friability, loss of rugae, the presence of petechiae, fissures, ulcerations, decreased elasticity, reduced lubrication or secretions, and a shortened, narrowed, and poorly distensible vaginal vault. Thinning and regression of the labia minora, retraction of the introitus, and involution of the hymenal carunculae can lead to dyspareunia. Other anatomical changes associated with GSM include reduced collagen content and hyalinization, thinning of the epithelium, and decreased elastin production. Pelvic and speculum exams may cause pain and bleeding.[2] Classic physical examination findings of atrophy may also include pale, dry, smooth, and shiny epithelium or inflammatory changes such as patchy erythema, petechiae, or increased visibility of blood vessels. There may also be friability, bleeding, and a thin, white, odorless discharge.[13]

Evaluation

Laboratory tests such as urinalysis and culture, sexually transmitted infection testing, and vaginal pathogen swabs may be employed to rule out genitourinary infections; they are typically not necessary for diagnosing GSM. Measuring estrogen levels via serum estradiol is also unreliable for diagnosing GSM, as current assays lack the sensitivity required for accurate detection.[14] Vaginal pH is typically greater than 5.0 in the absence of any infections or abnormal discharge, and atrophic changes in the vaginal epithelium include a shift from superficial cells to more basal cells.

One of the physical changes associated with GSM is having less than 5% superficial cells on the vaginal maturation index (VMI).[5] The VMI is derived from the microscopic evaluation of the vaginal epithelium, assessing the proportion of different vaginal epithelial cell types as follows:

• Parabasal cells are the least mature and are more prevalent when estrogen levels are low.
• Intermediate cells are moderately mature.
• Superficial cells are the most mature and predominate when estrogen levels are high.[15]

In early menopause, the VMI usually shows 30% intermediate cells, 5% superficial cells, and 65% parabasal cells. As atrophy progresses, the VMI may eventually display only parabasal cells. However, in clinical practice, neither the VMI nor vaginal pH measurement is necessary to diagnose GSM.[2] Moreover, the severity of GSM symptoms does not correlate well with vaginal pH or VMI. 

In 2020, the Menopause Society clarified that these laboratory tests are not essential for diagnosing GSM.[1] However, the use of a questionnaire like the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire, a brief yet comprehensive screening tool, may enhance the identification and treatment of GSM when used during annual wellness visits or when postmenopausal women present with vulvovaginal or genitourinary complaints.[16] Another tool frequently used to evaluate GSM symptoms is the Vaginal Health Index (VHI), which assesses vaginal secretions, pH, elasticity, hydration, and the epithelial mucous membrane condition. The VHI score ranges from 5 to 25, with lower scores indicating greater atrophy.[17]

Treatment / Management

GSM can be managed with various treatment modalities aimed at alleviating symptoms. These treatments are generally classified into nonhormonal and hormonal options. Below is an overview of the available treatments, including vaginal moisturizers, lubricants, vaginal estrogens, dehydroepiandrosterone (DHEA), systemic hormone replacement therapy, and ospemifene, an oral selective estrogen receptor modulator with both estrogen agonist and antagonist properties.[2] Patients with breast cancer deserve special mention as treatment of GSM presents a challenge due to the need to balance effective symptom management with the avoidance of estrogen-based therapies that could potentially exacerbate cancer risk.

Nonhormonal Treatments

Nonhormonal treatments such as vaginal and topical moisturizers and lubricants are considered the first-line therapy for GSM. Lubricants provide short-term relief, particularly for vaginal dryness during intercourse, while moisturizers offer longer-lasting effects and can be used daily or several times per week. Patients are also encouraged to engage in regular, safe sexual activity, as this helps maintain the health and integrity of the vaginal epithelium and flora. The use of moisturizers, lubricants, and regular sexual activity promotes vaginal health by supporting epithelial integrity and maintaining a balanced vaginal flora. The World Health Organization (WHO) recommends that personal moisturizers and lubricants have an osmolarity of less than 1200 mOsm/kg, as hyperosmolar products can be toxic to epithelial cells, potentially causing irritation and further compromising vaginal health.[2]

Local Estrogen Therapy 

This therapeutic option comes in many forms. These forms include vaginal creams, intravaginal tablets or capsules for more accurate dosing of estrogen, and a vaginal ring that releases small amounts of estrogen daily. All preparations are similarly effective in alleviating vaginal atrophy symptoms. Low-dose local estrogen therapy has not been shown to increase total systemic estrogen levels. Thus, vaginal estrogen allows for an excellent safety profile demonstrating a minimal to no increased risk of endometrial hyperplasia in healthy people.[8][18]

Patients usually have an improvement in symptoms after 2 to 4 weeks of local estrogen treatment.[19] However, some individuals may take 1 to 3 months to experience reduced symptoms. When urinary symptoms are present, vaginal estrogen is recommended. Progestin use and routine endometrial surveillance are not necessary for women using local estrogen therapy. However, any vaginal bleeding after menopause does require an investigation.[2]

As with all medication regimens, the risks and benefits should be discussed with patients before initiating any hormonal therapy. Local estrogen therapy has not been shown to increase circulating estrogen concentrations; it may be used in most patients to treat GSM. One contraindication for vaginal estrogen therapy is undiagnosed vaginal or uterine bleeding.[2]

Vaginal Dehydroepiandrosterone

DHEA comes in a low-dose vaginal insert that can be used daily for the treatment of dyspareunia from GSM. The vaginal mucosa transforms DHEA into estradiol and androgens. Daily use showed few adverse effects and improvement of GSM symptoms in menopausal women.[2]

Systemic Hormonal Therapy 

Systemic hormonal therapy becomes necessary for patients experiencing more widespread menopausal symptoms, such as night sweats and hot flashes, in addition to vaginal atrophy. For patients with these systemic symptoms, hormone replacement therapy (HRT)—including estrogen-progestin combinations or estrogen alone in patients who have had a hysterectomy—offers significant symptomatic improvement. Systemic HRT can promote the growth and revascularization of the vaginal epithelium, normalize vaginal pH, and increase lubrication. HRT can be administered systemically through oral or transdermal replacement. With an intact uterus, progesterone must be added to protect the endometrium. Study results indicate that systemic HRT alleviates symptoms of GSM in approximately 75% of cases, while local therapy is effective in 80% to 90% of cases. Although both therapies have comparable adverse events, local therapy is generally considered safer. In cases where moderate to severe vasomotor symptoms are also present, systemic hormonal therapy may be a particularly effective option.[2]

Ospemifene

Ospemifene is a selective estrogen receptor modulator (SERM) and an oral product approved for the treatment of GSM. This treatment is beneficial for patients with a history of hormone-sensitive cancer. SERMs can have a positive effect on the vaginal epithelium while having minimal to no impact on estrogen-dependent organs. Vasomotor symptoms are the most common adverse effect. Using ospemifene reduced recurrent urinary tract infections and improved symptoms and examination findings with GSM. Ospemifene is an estrogen agonist/antagonist, and its use at 60 mg daily has not been shown to increase endometrial cancer, venous thromboembolism, breast cancer, or breast cancer recurrence.[2] 

Additional Treatment Modalities 

Many other modalities are available to manage GSM, offering new options for symptom relief and improved patient outcomes. Pelvic floor physical therapy may also be used in combination with local estrogen therapy.[2] If there are anatomical vulvovaginal changes, vaginal dilators may be of use. This option is reserved for women who cannot take estrogen therapy and failed moisturizers and lubricants. Dilators have been shown to improve vaginal function.[20] 

More recent treatment modalities for GSM include laser and radiofrequency therapy. Laser therapy induces collagen formation by causing microtrauma to the tissue and can promote revascularization to restore vaginal moisture and elasticity. However, the safety and efficacy are uncertain.[17][21][22][23][24] Studies are underway to evaluate energy-based devices, including lasers like fractional carbon dioxide and Erbium-YAG and radio-frequency devices, but none are currently approved for specifically treating GSM.

Herbal products and hyaluronic acid products are ineffective for GSM treatment.[2] Longer and larger studies are needed looking at vaginal testosterone as it currently does not have sufficient data to recommend its use for GSM. Other proposed treatments for GSM include the active ingredient of the medicinal plant Ammi visnaga, or toothpick weed, a member of the carrot family, which causes vasodilation.[25] Bovine colostrum cream, prenylflavonoids, phytoestrogens, and aloe vera extract have all been considered alternative treatments, but more research is necessary before recommending any of these options.[17]

Treating Symptoms in Breast Cancer Patients

Patients with a personal history of breast cancer present several challenges related to GSM management. In patients who have had breast cancer, vaginal estrogen therapy for GSM is contraindicated per the Federal Drug Administration. However, the American College of Obstetricians and Gynecologists has endorsed its use and suggests safety when non hormonal therapy does not give satisfactory results. In a cohort study by McVicker, results indicate no evidence of an increase in mortality in breast cancer patients who used vaginal estrogen. These findings support vaginal estrogen therapy use for GSM in patients with breast cancer.[26] Vaginal DHEA has a cautionary label for use in patients with breast cancer because estrogen is a metabolite of DHEA, although it is not considered contraindicated. While ospemifene has shown a decreased risk of breast cancer and reduced recurrence rate, ospemifene is not recommended for GSM treatment in women with breast cancer because it has not been adequately studied. 

Differential Diagnosis

The differential diagnosis of GSM is essential for distinguishing it from other conditions with overlapping symptoms. Accurate diagnosis involves a thorough patient history, physical examination, and appropriate diagnostic tests to differentiate GSM from other conditions. Associated symptoms and signs of GSM overlap with many other gynecologic, urologic, and systemic conditions, making it more difficult for a clinician to contribute the symptoms solely to atrophy. Although these differential diagnoses must be ruled out, their presence does not exclude the additional diagnosis of GSM. Recurring symptoms or infections may be secondary to ongoing atrophy. Understanding these distinctions is crucial for implementing effective, targeted treatments and improving patient outcomes.

The differential diagnoses of GSM include the following:

• Allergic conditions

  • Contact dermatitis
  • Desquamative inflammatory vaginitis
• Inflammatory conditions

  • Lichen sclerosis
  • Erosive lichen planus
  • Cicatricial pemphigoid
• Infections                                             

  • Vulvovaginal candidiasis
  • Bacterial vaginosis
  • Trichomoniasis 
  • Herpes simplex virus
  • Chlamydia
  • Gonorrhea
  • Urinary tract infection
• Trauma
• Foreign bodies
• Malignancy
• Vulvodynia
• Vestibulodynia
• Chronic pelvic pain
• Provoked pelvic floor hypertonia (previously called vaginismus)
• Other medical conditions

  • Diabetes
  • Lupus erythematosus
  • Crohn disease
• Psychological disorders [2][4]                                                         

Prognosis

Patients who experience GSM can get significant symptomatic relief with treatment if the condition is diagnosed and discussed. Patients who do not undergo treatment will, unfortunately, continue to experience ongoing and progressive symptoms, which can increase frustration and lead to poor sexual lifestyles, recurrent infections, and a decreased quality of life. Clinicians can alleviate many distressing genitourinary symptoms and enhance the sexual health and quality of life of postmenopausal patients by educating them about, diagnosing, and effectively managing GSM. The choice of therapy should be based on the severity of symptoms, the efficacy and safety of available treatments for the individual patient, and the patient's preferences.[2]

Nonprescription, nonhormonal therapies often provide adequate relief for many patients with mild symptoms. For those with moderate to severe GSM, effective treatment options include low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy, and ospemifene. When using low-dose vaginal estrogen, DHEA, or ospemifene, the addition of progesterone is not necessary; however, long-term endometrial safety beyond 1 year has not been established in clinical trials for some of these treatment modalities.[2]

Complications

GSM can lead to several complications if left untreated or undertreated. These complications include chronic vaginal dryness, recurrent urinary tract infections, and painful sexual intercourse, which can significantly impact an individual's quality of life. Additionally, GSM may cause urinary incontinence, increased susceptibility to vaginal infections, and overall discomfort in daily activities. The physical symptoms may also lead to emotional and psychological distress, including reduced self-esteem and intimacy issues. Early recognition and appropriate treatment are crucial to prevent these complications and improve overall well-being.

Deterrence and Patient Education

Deterrence and patient education are critical in managing and preventing GSM. Educating patients about the early signs and symptoms of GSM can lead to timely intervention, reducing the severity of the condition. Healthcare professionals should emphasize the importance of regular gynecological check-ups, especially for patients who are postmenopausal, to monitor changes in the urogenital system. Patients should be informed about lifestyle modifications, such as maintaining regular sexual activity, which can help preserve vaginal health. Discussing nonhormonal and hormonal treatment options openly can empower patients to make informed decisions about their care. Addressing cultural and societal stigmas around GSM and encouraging open communication can also reduce patients' reluctance to seek treatment.

Pearls and Other Issues

GSM is a chronic condition that can significantly impact a patient's quality of life, affecting sexual function, relationships, and overall well-being. Early identification and proactive management are crucial, as GSM is often underdiagnosed due to insufficient screening and patient reluctance to discuss symptoms. A thorough history and physical examination, including a detailed sexual history, are essential to distinguish GSM from other urogenital conditions, such as infections or malignancies. Treatment should be individualized, incorporating both nonhormonal and hormonal therapies based on the patient's symptoms, preferences, and overall health.

Managing GSM typically occurs in an outpatient setting, with regular follow-ups to assess symptom progression and treatment efficacy. However, pitfalls such as underdiagnosis, inadequate treatment, and misattribution of symptoms can hinder effective management. Prevention strategies, including proactive screening and patient education about GSM’s causes, symptoms, and treatment options, are vital. Encouraging regular sexual activity, the use of vaginal moisturizers, and avoiding irritants can help maintain vaginal health and prevent the onset or worsening of GSM symptoms. Additionally, ongoing research into newer treatment options, such as local androgen therapy, offers promise for women who may not respond to traditional treatments.

Healthcare professionals should inform patients about GSM and the related urogenital changes that commonly accompany menopause. Many patients may not realize that symptoms like vaginal dryness, frequent urinary tract infections, discomfort during sexual activity, and other GSM-related issues are due to a decrease in estrogen levels. Unlike vasomotor symptoms, which often improve over time, GSM symptoms can persist or worsen without intervention. Educating women that effective and safe over-the-counter and prescription treatments are available is important.

Enhancing Healthcare Team Outcomes

Managing GSM necessitates an interprofessional approach that engages various healthcare professionals and advanced clinician, such as nurse practitioners and physician assistants, play pivotal roles in diagnosing GSM, formulating treatment plans, and educating patients. To offer personalized treatment options, they must remain up-to-date with the latest evidence-based practices, including nonhormonal and hormonal therapies. Nurses contribute by providing essential patient education, reinforcing treatment adherence, and monitoring the progression of symptoms. Pharmacists are key in ensuring the accurate prescription and dispensing of medications, offering critical information on drug interactions, adverse events, and the appropriate use of hormone replacement and other treatments. Coordinated care efforts should include regular follow-ups and ongoing monitoring of patient responses to therapy, allowing for adjustments to treatment plans as needed.

Ethical considerations in GSM management involve ensuring informed consent, respecting patient autonomy, and providing unbiased information about all available treatment options. Clinicians have a responsibility to prioritize patient safety, particularly when prescribing hormone therapies, by carefully considering contraindications and thoroughly discussing the potential risks and benefits with patients. Additionally, addressing any stigma or embarrassment that patients might feel when talking about GSM symptoms is essential, as well as creating a supportive and open environment where patients feel comfortable sharing their concerns.

Effective interprofessional communication is crucial for coordinating care and ensuring alignment within the treatment team. Regular case discussions and care conferences can help identify and address any gaps in care, ensuring that all aspects of the patient’s health are considered. To improve patient outcomes, the healthcare team must collaborate to educate patients about GSM, emphasizing the importance of early intervention and adherence to treatment. This effort includes addressing lifestyle factors that may exacerbate symptoms and promoting preventive measures, such as the regular use of moisturizers and lubricants and maintaining sexual activity to preserve vaginal health. The care team can enhance patient satisfaction and overall well-being by involving patients in decision-making and tailoring treatment plans to their specific needs and preferences.

Finally, continuous professional development and training in the latest GSM management strategies are essential for maintaining high team performance. This educational endeavor includes staying current with research, participating in multidisciplinary workshops, and engaging in quality improvement initiatives focused on GSM care. Interprofessional teams can effectively manage GSM and improve the quality of life for affected women by fostering a culture of collaboration, mutual respect, and shared responsibility.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Doust J, Huguenin A, Hickey M. Genitourinary Syndrome of Menopause: Does Everyone Have It? Clin Obstet Gynecol. 2024 Mar 01;67(1):4-12. [PubMed: 37972946]

2.

The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976-992. [PubMed: 32852449]

3.

Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clin Proc. 2017 Dec;92(12):1842-1849. [PubMed: 29202940]

4.

Woelber L, Prieske K, Mendling W, Schmalfeldt B, Tietz HJ, Jaeger A. Vulvar pruritus-Causes, Diagnosis and Therapeutic Approach. Dtsch Arztebl Int. 2020 Feb 21;116(8):126-133. [PMC free article: PMC7081372] [PubMed: 32181734]

5.

Reed SD. Foreword: Genitourinary Syndrome of Menopause. Clin Obstet Gynecol. 2024 Mar 01;67(1):1-3. [PubMed: 38281167]

6.

Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997 Oct;314(4):228-31. [PubMed: 9332260]

7.

Palacios S. Managing urogenital atrophy. Maturitas. 2009 Aug 20;63(4):315-8. [PubMed: 19493638]

8.

Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387-395. [PMC free article: PMC6074805] [PubMed: 30104904]

9.

Lindahl SH. Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health. 2014;6:307-12. [PMC free article: PMC3958523] [PubMed: 24648775]

10.

Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017 Apr;24(4):452-461. [PubMed: 27875388]

11.

Cipriani S, Maseroli E, Ravelli SA, Vignozzi L. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA. Climacteric. 2023 Aug;26(4):309-315. [PubMed: 37288964]

12.

Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R, Meriggiola MC. Vaginal Health in Menopausal Women. Medicina (Kaunas). 2019 Sep 20;55(10) [PMC free article: PMC6843679] [PubMed: 31547180]

13.

Balica AC, Cooper AM, McKevitt MK, Schertz K, Wald-Spielman D, Egan S, Bachmann GA. Dyspareunia Related to GSM: Association of Total Vaginal Thickness via Transabdominal Ultrasound. J Sex Med. 2019 Dec;16(12):2038-2042. [PubMed: 31542351]

14.

Demers LM, Hankinson SE, Haymond S, Key T, Rosner W, Santen RJ, Stanczyk FZ, Vesper HW, Ziegler RG., Endocrine Society. PATH (Partnership for Accurate Testing of Hormones). AACC (American Association for Clinical Chemistry). Measuring Estrogen Exposure and Metabolism: Workshop Recommendations on Clinical Issues. J Clin Endocrinol Metab. 2015 Jun;100(6):2165-70. [PMC free article: PMC5393513] [PubMed: 25850026]

15.

Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm LP, McClintock MK. Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States. Menopause. 2017 May;24(5):536-545. [PMC free article: PMC5403603] [PubMed: 27898651]

16.

Mastroianni J, Thompson JA, Shifren JL, Zuckerman AL, Pereira K. Improving the identification of genitourinary syndrome of menopause through the utilization of the Day-to-Day Impact of Vaginal Aging questionnaire. Menopause. 2020 Nov;27(11):1295-1301. [PubMed: 33110046]

17.

Sarmento ACA, Costa APF, Vieira-Baptista P, Giraldo PC, Eleutério J, Gonçalves AK. Genitourinary Syndrome of Menopause: Epidemiology, Physiopathology, Clinical Manifestation and Diagnostic. Front Reprod Health. 2021;3:779398. [PMC free article: PMC9580828] [PubMed: 36304000]

18.

Hill DA, Crider M, Hill SR. Hormone Therapy and Other Treatments for Symptoms of Menopause. Am Fam Physician. 2016 Dec 01;94(11):884-889. [PubMed: 27929271]

19.

Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia. Menopause. 2019 Nov;26(11):1259-1264. [PubMed: 31688572]

20.

Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med. 2011 Feb;8(2):549-59. [PubMed: 20722792]

21.

Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist. 2008 Mar;13(3):222-31. [PubMed: 18378532]

22.

Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M., Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-1156. [PMC free article: PMC4855283] [PubMed: 25415166]

23.

Wysocki S, Kingsberg S, Krychman M. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clin Med Insights Reprod Health. 2014;8:23-30. [PMC free article: PMC4071759] [PubMed: 24987271]

24.

Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016 Aug 31;2016(8):CD001500. [PMC free article: PMC7076628] [PubMed: 27577677]

25.

Khalil N, Bishr M, Desouky S, Salama O. Ammi Visnaga L., a Potential Medicinal Plant: A Review. Molecules. 2020 Jan 12;25(2) [PMC free article: PMC7024292] [PubMed: 31940874]

26.

McVicker L, Labeit AM, Coupland CAC, Hicks B, Hughes C, McMenamin Ú, McIntosh SA, Murchie P, Cardwell CR. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2024 Jan 01;10(1):103-108. [PMC free article: PMC10623297] [PubMed: 37917089]

Disclosure: Karen Carlson declares no relevant financial relationships with ineligible companies.

Disclosure: Hao Nguyen declares no relevant financial relationships with ineligible companies.